



Re

FEB 01 2000

PATENT  
Attorney Docket No.: UIA-027.01

GR 1645 Box seq WD  
[Handwritten signatures and initials]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 07 2000

In re the application of )  
 )  
Gregory Hageman, et al. )  
 )  
Application No.: 09/183,972 )  
 )  
Filed: October 29, 1998 )  
 )  
For: Therapeutics and Diagnostics For Ocular )  
Abnormalities )

Group Art Unit: 1645

Examiner: S. Turner

RECEIVED

FEB 01 2000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231, on January 24, 2000.

*Carmen Parra*  
Carmen Parra

Assistant Commissioner For Patents  
Washington, DC 20231

Sir:

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES

Applicants submit herewith a revised sequence listing which is fully compliant with the requirements of 37 CFR 1.821 through 1.825, in response to the Office Action mailed December 22, 1999. We submit herewith a Statement to Support Filing and Submission, a hard copy of the sequence listing and a computer readable form of the sequence listing (the diskette) as requested.

We believe that we have appropriately provided for fees due in connection with this submission, however, if there are any other fees due in connection with the filing of this Response, please charge the fees to our **Deposit Account No. 06-1448**.


If there are any questions after review of this paper, the Examiner can contact the undersigned at (617) 832-1242.

**RECEIVED**

FEB 07 2000

Respectfully Submitted,  
FOLEY, HOAG & ELIOT, LLP

January 24, 2000



---

Anita Varma  
Reg. No. 43,221  
Attorney for Applicants

Patent Group  
Foley, Hoag & Eliot, LLP  
One Post Office Square  
Boston, MA 02109  
Tel.: (617) 832-1000  
Fax: (617) 832-7000



Application No. 09/183972

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: See also Figs. 2-5 which do not comply

**Applicant Must Provide:**

- ☒ An Initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An Initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

COPY FOR [ ] File [ ] Applicant

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Atty. Docket No:U1A-027.01

In re patent application of

Hageman, Gregory S. et al.

Serial No. 09/183,972

Filed: October 29, 1998



For: THERAPEUTICS AND DIAGNOSTICS FOR OCULAR DISEASE BASED ON A NOVEL  
HUMAN GENE FAMILY

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently  
herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37  
C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the  
attached computer readable copy of the Sequence Listing, submitted in  
accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same;  
and


3. all statements made herein of their own knowledge are  
true and that all statements made on information and belief are believed to  
be true; and further, that these statements were made with the knowledge  
that willful false statements and the like so made are punishable by fine  
or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/183,972

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

January 13, 2000  
Date

  
James A. Coburn

**HARBOR CONSULTING**  
Intellectual Property Services  
1500A Lafayette Road  
Suite 262  
Portsmouth, N.H.  
800-318-3021